Condition
Spinal Muscular Atrophy 1
Total Trials
5
Recruiting
0
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (2)
Trial Status
Completed2
Active Not Recruiting2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07554924Phase 1Not Yet RecruitingPrimary
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
NCT06191354Not ApplicableActive Not RecruitingPrimary
A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
NCT01862042Not ApplicableCompletedPrimary
Palliative Care in Spinal Muscular Atrophy (SMA) 1
NCT03421977Active Not RecruitingPrimary
Long-Term Follow-up Study for Patients From AVXS-101-CL-101
NCT02122952Phase 1CompletedPrimary
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
Showing all 5 trials